Downtown BIZ sends 'parking angels' to help Winnipeggers transition to new system
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
14 minutes ago
- National Post
WELL Health Subsidiary WELLSTAR Provides Corporate Update Reflecting Improved Guidance and a Strong Acquisition Pipeline
Article content WELLSTAR continues to demonstrate strong growth and business momentum through its sustained organic growth and strong acquisition pipeline. The business is ahead of its internal expectations and has updated its guidance to $74 million (1) in total revenue and $22 million (1) in Adjusted EBITDA (2) for fiscal 2025, ending the year with total ARR of $62 million and an exit ARR (3) of approximately $80 million. WELLSTAR has executed three LOIs for acquisitions that will drive approximately $15 million in ARR, $16 million in revenues and over $5 million in Adjusted EBITDA on an annualized basis. WELLSTAR's recently launched Nexus AI™ solution has generated significant early momentum. As a pre-qualified vendor for Canada Health Infoway's AI Scribe Program, eligible primary care clinicians can now receive a fully-funded Nexus AI license for 12 months. Article content VANCOUVER, British Columbia & TORONTO — WELL Health Technologies Corp. (TSX: WELL) (' WELL ' or the ' Company '), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients, is pleased to provide a corporate update highlighting continued momentum across its majority-owned subsidiary, WELLSTAR Technologies Corp. (' WELLSTAR '). WELLSTAR is tracking ahead of internal expectations, supported by robust organic growth, a strong acquisition pipeline, and accelerating adoption of its Nexus AI solution. Article content WELLSTAR continues to demonstrate strong growth and execution, fueled by accelerating demand for its digital health solutions and steady progress across its platform. The business is tracking ahead of internal expectations and has updated its guidance for fiscal 2025 to over $74 million (1) in revenue and $22 million (1) in Adjusted EBITDA (2). WELLSTAR is also expected to end the year with total annual recurring revenue (ARR) of approximately $62 million and an exit ARR (3) of approximately $80 million, supported by robust organic expansion, continued adoption of its AI-powered tools, and inclusive of completing three acquisitions that are currently in signed LOI stage. Article content Amir Javidan, CEO of WELLSTAR commented, 'We've had an excellent first half to 2025 as both our organic and inorganic growth engines are levelling up and are poised to deliver an outstanding, breakout performance for WELLSTAR in 2025. At the beginning of the year, we set an ambitious goal of reaching $100M in revenues on a run-rate basis in the next couple of years and based on the latest forecasts, we believe we may be approaching that goal a few quarters earlier than previously anticipated. Our current goal for year-end exit ARR for fiscal 2025 is $80 million which would represent a 50% increase over last year's exit ARR figure. Article content Darren Hoegler, CFO of WELLSTAR commented, 'This upward revision reflects stronger-than-expected traction across WELLSTAR's core product suite as well as strong execution in the company's capital allocation program. We currently have three signed LOIs with targets that all deliver high-margin SaaS solutions and would be highly accretive to our business. I'm also pleased to report that the two acquisitions that were completed in Q4 2024 are both operating well and tracking in alignment with or ahead of our plan. Our objective is to ensure disciplined execution and that the company continues to be positioned as a category leader in Canadian digital health, delivering durable, capital-efficient growth with significant operating leverage over time.' Article content Three LOIs Executed as WELLSTAR Executes on Deep Acquisition Pipeline Article content WELLSTAR has executed three letters of intent (LOIs) for acquisitions that are expected to contribute approximately $15 million in ARR, $16 million in revenue, and over $5 million in Adjusted EBITDA on an annualized run-rate basis. These prospective additions reflect WELLSTAR's continued focus on disciplined, accretive growth through the acquisition of complementary digital health assets that strengthen its core platform and expand its national footprint. Article content The acquisitions are aligned with WELLSTAR's long-term strategy to build a technology-enabled healthcare infrastructure that is efficient, scalable, and outcomes-driven. Each target adds strategic value by extending WELLSTAR's clinician enablement capabilities. The integrated nature of WELLSTAR's platform enables smooth onboarding and operational alignment, allowing new assets to benefit from shared infrastructure and drive incremental impact across the broader business. Article content WELLSTAR continues to advance a deep and well-qualified acquisition pipeline, with additional opportunities under review. Article content Strong Early Traction for Nexus AI with Clinicians Nationwide Article content Since its launch on May 7, 2025, Nexus AI has seen strong adoption, with over 2,400 providers signed up across primary care clinics, hospitals, and regional health authorities. Nexus AI's first feature, an ambient medical scribe for real-time clinical documentation, is already demonstrating meaningful value for providers by reducing administrative burden and cognitive load. AI medical scribe technology has been shown to save providers up to two hours per day in charting and documentation (4). Article content Nexus AI serves as the central platform for WELLSTAR's expanding suite of AI-powered capabilities, including disease detection, medical coding and billing automation, and clinical decision support. Its compatibility with Canada's leading EMRs positions it as a scalable infrastructure layer for modern, intelligent healthcare delivery. Article content Clinician engagement with Nexus AI is expected to contribute to WELLSTAR's recurring SaaS revenue and margin profile as deployments scale. Just as importantly, the platform's ability to orchestrate complex clinical workflows in an intuitive and context-aware way supports broader system-level efficiency and provider satisfaction. As a pre-qualified vendor of the Canada Health Infoway AI Scribe Program, eligible primary care clinicians across Canada will receive a fully-funded license for 12 months of Nexus AI. WELLSTAR recognizes this as a transformative opportunity to advance Canada's vision of connected care, where AI-enabled technologies reduce physician burnout, improve patient experience, and allow providers to focus more on engagement and less on documentation. By delivering accurate, secure documentation at the point of care, Nexus AI empowers providers to reclaim meaningful patient connections and supports a broader effort to integrate AI technologies that promote more connected, patient-centred care. Footnotes: Article content WELLSTAR's guidance of $74 million in revenue and $22 million in Adjusted EBITDA in fiscal 2025 includes the impact from the three LOIs noted herein which will contribute approximately $4 million in revenue and $1 million in Adjusted EBITDA for inclusion in fiscal 2025. Note that this figure does not include certain shared services that are provided by WELL Health to WELLSTAR. Adjusted EBITDA is a non-GAAP financial measure. Please refer to WELL's most recent Management's Discussion and Analysis (MD&A), available under the Company's profile on SEDAR+ at for further details including definitions and reconciliations to the nearest IFRS measure. Exit ARR or Annual Recurring Revenue is based on the Company's revenue run-rate or ARR as annualized based on the last quarter of the year. The projected Exit ARR of approximately $80 million includes contribution from the three LOIs noted herein. Source: OntarioMD, AI scribes show promising results in helping family doctors and nurse practitioners spend more time with patients and less time on paperwork, September 11, 2024. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Article content Hamed Shahbazi Article content Chief Executive Officer, Chairman and Director Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Forward-Looking Statements Article content Certain statements in this press release, constitute 'forward-looking information' and 'forward looking statements' (collectively, 'forward looking statements') within the meaning of applicable Canadian securities laws, including the guidance related to revenue and adjusted EBITDA, and the expected pipeline of future acquisition targets (and the associated run-rate revenue). Forward-looking statements are necessarily based upon management's expectations, while considered reasonable by WELL as of the date of such statements, are outside of WELL's control and are inherently subject to business, economic and other uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to the ability to continue to offer its products and services, complete the acquisitions, and the acquisition companies having the expected revenue and Adjusted EBITDA profiles based on WELL's diligence. Article content Known and unknown risk factors, many of which are beyond the control of WELL could cause the actual plans to differ materially from the results implied by such forward-looking statements. Such risk factors include losing customers to competitors, cybersecurity threats which prevent WELLSTAR from being able to continually offer its products, not completing the three acquisitions discussed above, and the other risks discussed under the section entitled 'Risk Factors' in WELL's most recent annual information form, which is available under the Company's respective SEDAR+ profile at which could affect WELL's and WELLSTAR's business. The risk factors are not intended to represent a complete list of the factors that could affect WELL or WELLSTAR and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. Article content Article content Article content Article content Contacts Article content For more information: Article content Article content Tyler Baba Article content Article content Article content
National Post
14 minutes ago
- National Post
Generation Mining Appoints Kyle Kuntz to Board of Directors Strengthening Development and Construction Expertise
Article content TORONTO — Generation Mining Limited (TSX:GENM)(OTCQB: GENMF) (' Generation Mining ' or the ' Company ') is pleased to announce the appointment of Kyle Kuntz to its Board of Directors. Article content Mr. Kuntz is a mining project executive with over a decade of experience leading large-scale mining developments across North America. He currently holds the position of Vice President, Projects at Equinox Gold Corp. Before joining Equinox, he served as Director, Projects at Marathon Gold Corp., where he remained through its acquisition by Calibre Mining and the subsequent merger with Equinox. During his tenure at Calibre, he was responsible for overseeing the construction of the Valentine Gold Project. Earlier in his career, he held key roles with JDS Energy & Mining Inc., the Nuna Group of Companies, and Stantec. Mr. Kuntz brings deep expertise in transforming mineral projects from feasibility studies into operational assets, with a focus on project management, engineering leadership, procurement strategies, and construction execution. Article content Article content 'We are delighted to welcome Kyle to our Board of Directors,' said Kerry Knoll, Chairman of Generation Mining. 'His leadership at the Valentine Gold Project and his deep understanding of the technical, regulatory, and stakeholder engagement processes will strengthen our Board as we advance our Marathon Copper-Palladium Project toward construction. His hands-on experience guiding a major Canadian mining project through construction brings added technical capacity to our Board as Generation Mining enters its next phase of growth.' Article content 'I'm excited to join the Generation Mining Board and contribute to the advancement of the Marathon Project,' said Mr. Kuntz. 'With the growing importance of critical minerals like copper and palladium, this project is strategically positioned to play a key role in Canada's resource future.' Article content About the Company Article content Generation Mining's focus is the development of the Marathon Project, a large undeveloped copper-palladium deposit in Northwestern Ontario. The Marathon Property covers a land package of approximately 26,000 hectares, or 260 square kilometers. Generation Mining is dedicated to fostering a greener future by promoting sustainability, empowering communities, and delivering value to our stakeholders. Article content The Feasibility Study (the ' Technical Report ') estimated a Net Present Value (using a 6% discount rate) of C$1.07 billion, an Internal Rate of Return of 28%, and a 1.9-year payback based on the 3-yr trailing average metal prices at the effective date of the Technical Report. Over the anticipated 13-year mine life, the Marathon Project is expected to produce 2,161,000 ounces of palladium, 532 million lbs of copper, 488,000 ounces of platinum, 160,000 ounces of gold and 3,051,000 ounces of silver in payable metals. For more information, please review the Feasibility Study filed under the Company's profile at or on the Company's website at Article content Qualified Person Article content The scientific and technical content of this news release has been reviewed and approved by Daniel Janusauskas, Technical Services Manager of Generation PGM Inc., a wholly-owned subsidiary of the Company, and a Qualified Person as defined by Canadian Securities Administrators National Instrument 43-101 Standards of Disclosure for Mineral Projects. Article content Forward-Looking Information Article content This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as 'forward-looking statements)'. Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'continues', 'forecasts', 'projects', 'predicts', 'intends', 'anticipates', 'targets' or 'believes', or variations of, or the negatives of, such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'should', 'might' or 'will' be taken, occur or be achieved, including statements relating to the Article content including statements relating to projected capital and operating costs (including the AISC); the timing and volume of payable metal production and revenues; and the economic analysis and results (including NPVs and payback periods). Article content Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include the timing for a construction decision; the progress of development at the Marathon Project, including progress of project expenditures and contracting processes, the Company's plans and expectations with respect to liquidity management, continued availability of capital and financing, the future prices of palladium, copper and other commodities, permitting timelines, exchange rates and currency fluctuations, increases in costs, requirements for additional capital, and the Company's decisions with respect to capital allocation, inflation, global supply chain disruptions, global conflicts, including the wars in Ukraine and Israel, the project schedule for the Marathon Project, key inputs, staffing and contractors, continued availability of capital and financing, uncertainties involved in interpreting geological data and the accuracy of mineral reserve and resource estimates, environmental compliance and changes in environmental legislation and regulation, the Company's relationships with Indigenous communities, results from planned exploration and drilling activities, local access conditions for drilling, and general economic, market or business conditions, as well as those risk factors set out in the Company's annual information form for the year ended December 31, 2024, and in the continuous disclosure documents filed by the Company on SEDAR+ at Article content Article content . Article content Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR+ at Article content Article content Article content Article content Article content Contacts Article content For further information please contact: Article content
National Post
14 minutes ago
- National Post
ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial
Article content Experienced hematologist-oncologist to lead strategic and medical oversight of clinical development program Article content SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the 'Company') (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company's leadership team as Chief Medical Officer ('CMO'), effective July 14, 2025. Article content Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academic experience based in Saskatoon, Saskatchewan, specializing in blood cancers and stem cell transplantation. As CMO, Dr. Stakiw will provide clinical leadership and oversee the scientific integrity of ZYUS' clinical development program. Her appointment marks a significant step as the Company advances its lead drug product candidate, Trichomylin® softgel capsules, through its pivotal Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) trial. Article content 'Dr. Stakiw brings a wealth of clinical expertise and firsthand patient experience in oncology care, which is instrumental as we advance our Phase 2 UTOPIA trial,' said Brent Zettl, President and CEO of ZYUS. 'Her strong understanding of research and treatment development will be invaluable in addressing the critical need for effective, non-opioid cancer pain therapies and supporting our commitment to improving patient outcomes.' Article content 'I'm pleased to take on the role of Chief Medical Officer at ZYUS,' said Dr. Julie Stakiw. 'ZYUS' commitment to developing innovative, non-opioid alternatives for cancer pain aligns with my passion for improving patient care. I look forward to contributing my clinical and research experience to support the advancement of the Phase 2 UTOPIA trial and help bring meaningful new options to patients facing cancer pain.' Article content Dr. Stakiw completed her medical degree and internal medicine residency at the University of Saskatchewan, followed by specialized training in hematology at Queen's University and a clinical fellowship in lymphoma and stem cell transplantation at Princess Margaret Hospital in Toronto. She has held several key leadership positions including Provincial Leader of Hematology, Medical Director of Saskatchewan's Blood and Marrow Transplant Program, and Medical Director of the Saskatoon Cancer Clinic. Dr. Stakiw also previously served as Director of Clinical Trials at a regional cancer centre in Ontario and as Director of Patient Research and Innovation for the Saskatchewan Cancer Agency. Known for her patient-centered approach and expertise in managing complex hematologic conditions such as multiple myeloma and leukemia, Dr. Stakiw continues to serve as a Clinical Professor in Hematological Oncology at the University of Saskatchewan while maintaining an active clinical practice. Her extensive clinical and leadership experience will be instrumental in advancing ZYUS' clinical development program. Article content Dr. Stakiw succeeds Dr. Lionel Marks de Chabris, who is stepping down as CMO and will continue to provide strategic guidance as Chair of the Clinical Research Advisory Committee. The Company is grateful for Dr. Marks de Chabris's ongoing leadership and commitment to advancing ZYUS' mission. Article content About ZYUS Life Sciences Corporation Article content ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Article content Cautionary Note Regarding Forward-Looking Statements Article content This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin® softgel capsules, introduce products that act as alternatives to current pain management therapies, advance Phase 2 clinical development of Trichomylin® softgel capsules and build shareholder value. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin® softgel capsules, introduce products that act as alternatives to current pain management therapies, advance Phase 2 clinical development of Trichomylin® softgels, and build shareholder value are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies or advance Phase 2 clinical development of Trichomylin® softgels. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Article content Article content Article content Article content Article content Contacts Article content For more information, please contact: Article content ZYUS Media Inquiries media@ 1-833-651-7723 Article content
